Deans' stroke musings: Diphenhydramine: It is time to say a final goodbye(Benadryl,Dimedrol, Daedalon, Nytol, and Vivinox)

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, June 5, 2025

Diphenhydramine: It is time to say a final goodbye(Benadryl,Dimedrol, Daedalon, Nytol, and Vivinox)

Your competent? doctor warned you against this almost a decade ago, right? NO? So, you DON'T have a functioning stroke doctor or hospital, do you?

Allergy drugs may hurt your brain, study shows April 2016

The latest here:

Diphenhydramine: It is time to say a final goodbye

James H. Clark, MD^a jclark79@jh.edu ∙ Eli O. Meltzer, MD^b ∙ Robert M. Naclerio, MD^a

Cover Image - World Allergy Organization Journal, Volume 18, Issue 2

Download PDF

Cite

Abstract

Diphenhydramine, once a pioneering antihistamine, is now overshadowed by second-generation antihistamines with similar efficacy and fewer adverse effects. Current data suggest that the adverse side-effect profile of diphenhydramine is higher among children and older adults. This has led to countries such as Germany and Sweden restricting access to first-generation antihistamines and societal guidelines advocating for the use of second-generation antihistamines. Despite its well-documented problematic therapeutic ratio, diphenhydramine remains available in over 300 formulations, most of which are over-the-counter.

Based on a comprehensive evaluation of practice patterns and the prevalence and incidence of adverse clinical events, we believe that diphenhydramine has reached the end of its life cycle, and in its class of therapies it is a relatively greater public health hazard. We recommend it should no longer be widely prescribed or continue to be readily available over the counter.

Further info on this:

"Anything you would use Benadryl for can be replaced with cetirizine (Zyrtec), loratadine (Claritin), fexofenadine (Allegra), or [levocetirizine (Xyzal)]," David Stukus, MD, of Nationwide Children's Hospital in Columbus, Ohio, wrote in an Instagram post about the paper. "If you're asking if any of these are safer or better, the answer is YES!!!"